Home > Riviste > Minerva Cardioangiologica > Fascicoli precedenti > Articles online first > Minerva Cardioangiologica 2017 Mar 01

ULTIMO FASCICOLO
 

ARTICLE TOOLS

Estratti

MINERVA CARDIOANGIOLOGICA

Rivista sulle Malattie del Cuore e dei Vasi


Official Journal of the Italian Society of Angiology and Vascular Pathology
Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,752


eTOC

 

Minerva Cardioangiologica 2017 Mar 01

DOI: 10.23736/S0026-4725.17.04369-9

Copyright © 2017 EDIZIONI MINERVA MEDICA

lingua: Inglese

When surgery is not an option: is there a clinical need for transcatheter tricuspid valve therapies?

Alec VAHANIAN , Jean M. JULIARD, Eric BROCHET

Cardiology Department, Hôpital Bichat, Université Paris VI, Paris, France


PDF  


Severe functional tricuspid regurgitation (FTR) is frequent and carries a poor prognosis when left untreated. The strategy in symptomatic patients should be decided by a Heart Team which will choose between valve surgery, transcatheter intervention, heart transplantation or palliative medical therapy.
The field of application of transcatheter tricuspid valve therapy will certainly focus on inoperable or high-risk patients first, especially those with FTR occurring late after left-sided valve surgery. If surgery is contraindicated because of multiple comorbidities interventions which are likely to be “futile” should be avoided. Conversely, if life expectancy is acceptable, it is attractive to envisage percutaneous intervention.
Thus there is a clinical need for transcatheter tricuspid valve therapies when surgery is not an option. Controlled clinical studies are necessary to show the safety profile and the performance of the new transcatheter procedures and define their potential role.

inizio pagina

Publication History

Per citare questo articolo

Corresponding author e-mail

alec.vahanian@aphp.fr